| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net product revenue | 624,677 | - |
| Cost of product sold | 129,777 | - |
| Research and development | 102,988 | - |
| Sales and marketing | 84,443 | - |
| General and administrative | 54,986 | - |
| Depreciation and amortization | 17,903 | - |
| Stock-based compensation | 34,668 | - |
| Interest expense | 11,103 | - |
| Interest income | 16,070 | - |
| Income tax expense | 38,103 | - |
| Other segment items | 30,575 | - |
| Net income | 136,201 | 85,336 |
| Depreciation | 20 | 13 |
| Intangible amortization | 17,883 | 11,922 |
| Acquired in-process research & development (ipr&d) expense | 30,000 | 15,000 |
| Stock-based compensation | 34,923 | 23,954 |
| Stock appreciation rights market adjustment | -255 | -110 |
| Debt issuance costs amortization | 490 | 329 |
| Deferred taxes | -14,677 | -10,796 |
| Amortization of premiums and accretion of discounts on investment securities | 1,240 | 904 |
| Other non-cash expenses | 923 | 932 |
| Trade receivables | 17,618 | 9,948 |
| Inventory | -316 | -1,098 |
| Prepaid expenses and other assets | -6,942 | 5,586 |
| Trade payables | 12,597 | 14,557 |
| Other liabilities | 15,543 | -12,483 |
| Net cash provided by operating activities | 222,048 | 113,314 |
| Purchase of investment securities | 67,313 | 43,032 |
| Proceeds from maturities and sales of investment securities | 60,500 | 40,937 |
| Purchase of property and equipment | 203 | 132 |
| Payment of upfront fee related to research collaboration, option and license agreement | 15,000 | 15,000 |
| Net cash used in investing activities | -22,016 | -17,227 |
| Principal repayment of long-term debt | 11,250 | 7,500 |
| Payments of employee withholding taxes related to stock-based awards | 2,341 | 2,341 |
| Proceeds from exercised options | 7,557 | 6,803 |
| Net cash used in financing activities | -6,034 | -3,038 |
| Net increase in cash, cash equivalents, and restricted cash | 193,998 | 93,049 |
| Cash and cash equivalents at beginning of period | 453,271 | - |
| Cash and cash equivalents at end of period | 647,269 | - |
Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY)